Getinge Interim Report April-June 2025: Continuing positive trend with stable organic sales growth in all business areas and regions

GOTHENBURG, Sweden, July 18, 2025 /PRNewswire/ -- "The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 4.1% while order intake rose by 4.4% organically.

Business area Acute Care Therapies continues to be successful in handling the increased demand for ventilators, and the order intake in ECLS consumables remains high. The positive trend for Sterile Transfer in Life Science strengthened during the quarter, while the rationalizations in Getinge's Bio-Processing business are fully underway.

"This means that we will be well positioned for profitable growth in Bio-Processing when demand returns. In Surgical Workflows, Infection Control and Digital Health Solutions delivered significant growth," says Mattias Perjos, President & CEO.

Paragonix, acquired in the autumn of 2024, continues to impress, with another sales record in the quarter. The operations also made a positive contribution to Getinge's EBITA margin, slightly earlier than expected.

Another important milestone for Getinge was the first use of the next generation of endoscopic vessel harvesting (EVH) product, Vasoview Hemopro 3, in clinical procedures in the US.

"The results were positive, and we expect to start deliveries on a larger scale during the third quarter," Perjos tells. "In Life Science, we launched a new washer and in Surgical Workflows we continue to strengthen our offering in consumables, where we have achieved high growth. Surgical Workflows also entered an exciting partnership ...